Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man

European Journal of Clinical Pharmacology

Volumn 52, Issue 2, 1997, Pages 115-120

  Flesch, G ^a   Muller Ph ^a   Lloyd, P ^b  

^a CIBA GEIGY LTD   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

bioavailability; deconvolution; healthy volunteers; Valsartan; pharmacokinetics

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; VALSARTAN;

ADULT; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SOLUTION; DRUG URINE LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AVAILABILITY; CAPSULES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PILOT PROJECTS; RECEPTORS, ANGIOTENSIN; SOLUTIONS; TETRAZOLES; VALINE;

EID: 0030979588     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050259     Document Type: Article

References (12)

1. Flesch G, Mueller Ph, Hell F, Degen P, Howald H, Dieterle W (1996) Absolute oral biovailability of valsartan in healthy volunteers. Eur J Drug Metab Pharmacokinet: 60 (abstract 163)
2. Criscione L, Bradley WA, Buehlmayer P, Whitebread S, Glazer R, Lloyd P, Mueller P, DeGasparo M (1995) Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 13: 230-250
3. 1-receptor subtype. Br J Pharmacol 110: 761-771
4. Furukawa Y, Kishimoto S, Nishikawa K (1982) Hypotensive imidazole-5-acetic acid derivatives. Patent issued to Takeda Chemical Industries, Ltd, Osaka, Japan. US patent 4-340, 598 and 4-355, 040
5. Buehlmayer P, Criscione L, Fuhrer W, Furet P, DeGasparo M, Stutz S, Whitebread S (1991) Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivativies. J Med Chem 34: 3105-3114
6. Duncia JV, Carini DJ, Chiu AT, Johnson AL, Price WA, Wong PC, Wexler RR, Timmermans PB (1992) A potent, orally active nonpeptide angiotensin II receptor antagonist. Med Res Rev 12: 149-191
7. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD (1995) Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP 3174 in humans. Clin Pharmacol Ther 58: 641-649
8. 14C-radiolabelled preparation. Xenobiotica 27: 59-71
9. Flesch G, Müller Ph, Degen P, Lloyd P, Dieterle W (1993) Repeated dose pharmacokinetics of valsartan. a new angiotensin-II antagonist, in healthy subjects. Eur J Drug Metab Pharmacokinet 18 (abstract 256)
10. Gibaldi M, Perrier D (1982) Pharmacokinetics. Dekker, New York
11. Veng Pedersen P (1988) Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? I. General considerations. J Pharmacokinet Biopharm 16: 413-472
12. Cutler VHL (1978) Linear systems analysis in pharmacokinetics. J Pharmacokinet Biopharm 6: 265-282